Latest News in the pharma Industry

Research & Development

Merck trial studying Keytruda in advanced bladder cancer meets primary endpoint and stops early

Merck trial studying Keytruda in advanced bladder cancer meets primary endpoint and stops early

23 Oct 2016

Keytruda is the first immunotherapy to show improved overall survival compared with chemotherapy in urothelial cancer.

Read more 
Positive results from two pivotal Phase 3 studies of Revefenacin for the treatment of COPD

Positive results from two pivotal Phase 3 studies of Revefenacin for the treatment of COPD

20 Oct 2016

Top-line results across more than 1,250 moderate to very severe COPD patients confirmed that both Phase III studies met their primary efficacy endpoint.

Read more 
SOTIO and NBE Therapeutics sign collaboration and license agreement for next-generation ADCs

SOTIO and NBE Therapeutics sign collaboration and license agreement for next-generation ADCs

20 Oct 2016

Collaboration will focus on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets.

Read more 
Horizon Discovery signs subscription-based licensing agreement for biomanufacturing cell lines

Horizon Discovery signs subscription-based licensing agreement for biomanufacturing cell lines

19 Oct 2016

The subscription deal, which is valued at a minimum of £500,000, provides partner access to Horizon's engineered cell lines.

Read more 
FDA approves Genentech’s cancer immunotherapy Tecentriq for people with a specific type of metastatic lung cancer

FDA approves Genentech’s cancer immunotherapy Tecentriq for people with a specific type of metastatic lung cancer

19 Oct 2016

First and only anti-PDL1 cancer immunotherapy approved by the FDA for metastatic non-small cell lung cancer.

Read more 
A new player in appetite control

A new player in appetite control

18 Oct 2016

Brain cells that provide structural support also influence feeding behavior, study shows.

Read more 
Lilly partners with the National Cancer Institute to accelerate cancer research through new program under Cancer Moonshot initiative

Lilly partners with the National Cancer Institute to accelerate cancer research through new program under Cancer Moonshot initiative

18 Oct 2016

New database provides access to oncology studies in an effort to speed medicines to patients.

Read more 
Pfizer to present new data on Xeljanz for ulcerative colitis at UEG Week 2016

Pfizer to present new data on Xeljanz for ulcerative colitis at UEG Week 2016

16 Oct 2016

Includes an oral presentation looking at the effect of prior treatment with tumour necrosis factor inhibitors on efficacy endpoints.

Read more 
FDA grants Orphan Drug Designation for True North Therapeutics' lead product candidate, TNT009

FDA grants Orphan Drug Designation for True North Therapeutics' lead product candidate, TNT009

13 Oct 2016

TNT009 is currently in clinical development for the treatment of autoimmune hemolytic anemia, including Cold Agglutinin Disease (CAD), a form of autoimmune hemolytic anemia.

Read more 
Study finds Ebola treatment ZMapp holds promise, although results not definitive

Study finds Ebola treatment ZMapp holds promise, although results not definitive

13 Oct 2016

Trial shows rigorous clinical research feasible during a public health emergency.

Read more 
Aptuit expands capabilities and capacity in formulation development and safety assessment

Aptuit expands capabilities and capacity in formulation development and safety assessment

13 Oct 2016

Company's continued expansion allows it to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based drug product development.

Read more 
PhoreMost and Cambridge Uni collaborate to identify innovative drug targets for neurodegenerative disease

PhoreMost and Cambridge Uni collaborate to identify innovative drug targets for neurodegenerative disease

12 Oct 2016

The studies have the potential to reveal novel insights for previously unknown autophagy signalling components, which could suggest rapid and innovative starting points for new drug treatments.

Read more